3:12 PM
 | 
May 15, 2018
 |  BC Extra  |  Financial News

Xenikos raises $30M series B

Xenikos B.V. (Nijmegen, the Netherlands) raised $30 million in a series B round co-led by new investors Medicxi and RA Capital.

In early 2019, the company plans to start Phase III testing in the U.S. and EU of lead candidate T-Guard to treat steroid-resistant, acute graft-versus-host disease (GvHD).

T-Guard is a fusion protein linking anti-CD3 and anti-CD7 mAbs with ricin A toxin. The therapy has Orphan Drug designation in the U.S. and EU.

Medicxi's Jon Edwards and RA Capital's Jake Simson will join Xenikos' board.

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

Purchase this article for limited one-time distribution and website posting

$750 USD